SCHEMBL1898040

SCHEMBL1898040

CN1C(=O)NC(=O)C12CCc1cc(C(=O)N[C@@H]3Cc4ccc5[nH]ncc5c4CN(CC(C)(C)C)C3=O)ccc1C2

nearest known ligand 0.51

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ CALCRL Q16602 19/20 0.51
▸ RAMP1 O60894 2/20 0.33
▸ ITGB3 P05106 1/20 0.30
▸ ITGAV P06756 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1898041 0.78 CALCRL (0.41) CALCRL
SCHEMBL2211079 0.71 CALCRL (0.59) CALCRL
SCHEMBL1892444 0.70 CALCRL (0.48) CALCRLRAMP1
SCHEMBL13792179 0.70 CALCRL (0.66) CALCRL
SCHEMBL13792123 0.70 CALCRL (0.69) CALCRL
SCHEMBL13987074 0.69 CALCRL (0.52) CALCRL
SCHEMBL2210420 0.69 CALCRL (0.52) CALCRL
SCHEMBL2209884 0.69 CALCRL (0.52) CALCRL
SCHEMBL3881732 0.69 CALCRL (0.51) CALCRL
SCHEMBL3881738 0.69 CALCRL (0.51) CALCRL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2091533-B1 CONSTRAINED SPIROCYCLIC COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2012-11-28 — — EP disclosed
EP-2091533-B1 CONSTRAINED SPIROCYCLIC COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2012-11-28 — — EP disclosed
US-7951795-B2 Constrained spirocyclic compounds as CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2011-05-31 — — US disclosed
US-7951795-B2 Constrained spirocyclic compounds as CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2011-05-31 — — US disclosed
US-7951795-B2 Constrained spirocyclic compounds as CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2011-05-31 — — US disclosed
US-20100069359-A1 CONSTRAINED SPIROCYCLIC COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2010-03-18 — — US disclosed
US-20100069359-A1 CONSTRAINED SPIROCYCLIC COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2010-03-18 — — US disclosed
US-20100069359-A1 CONSTRAINED SPIROCYCLIC COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2010-03-18 — — US disclosed
WO-2008073251-A1 CONSTRAINED SPIROCYCLIC COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2008-06-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069359-A1 CONSTRAINED SPIROCYCLIC COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS CALCRL, BDKRB1, CALCR CALCRL 1/4885RAMP1 20/4885ITGB3 1945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback